| RRC ID |
68857
|
| 著者 |
Miyauchi M, Sasaki K, Kagoya Y, Taoka K, Masamoto Y, Yamazaki S, Arai S, Mizuno H, Kurokawa M.
|
| タイトル |
CAMK2G is identified as a novel therapeutic target for myelofibrosis.
|
| ジャーナル |
Blood Adv
|
| Abstract |
Although JAK1/2 inhibition is effective into alleviating symptoms of myelofibrosis (MF), it does not result in the eradication of MF clones, which can lead to inhibitor-resistant clones emerging during the treatment. Here we established iPS cells derived from MF patient samples (MF-iPSCs) harboring JAK2 V617F, CALR type 1, or CALR type 2 mutations. We demonstrated that these cells faithfully recapitulate the drug sensitivity of the disease. These cells were utilized for chemical screening and calcium/calmodulin-dependent protein kinase 2 (CAMK2) was identified as a promising therapeutic target. MF model cells and mice induced by MPL W515L, another type of mutations recurrently detected in MF patients were used to elucidate the therapeutic potential of CAMK2 inhibition. CAMK2 inhibition was effective against JAK2 inhibitor-sensitive and JAK2 inhibitor-resistant cells. Further research revealed CAMK2 gamma subtype was important in MF model cells induced by MPL W515L. We showed that CAMK2G hetero knockout in the primary bone marrow cells expressing MPL W515Ldecreased colony-forming capacity. CAMK2G inhibition with berbamine, a CAMK2G inhibitor, significantly prolonged survival and reduced disease phenotypes such as splenomegaly and leukocytosis in a MF mouse model induced by MPL W515L. We investigated the molecular mechanisms underlying the therapeutic effect of CAMK2G inhibition and found that CAMK2G is activated by MPL signaling in MF model cells and is an effector in the MPL-JAK2 signaling pathway in these cells. These results indicate CAMK2G plays an important role in MF, and CAMK2G inhibition may be a novel therapeutic strategy that overcomes resistance to JAK1/2 inhibition.
|
| 巻・号 |
6(5)
|
| ページ |
1585-1597
|
| 公開日 |
2022-3-8
|
| DOI |
10.1182/bloodadvances.2020003303
|
| PII |
476895
|
| PMID |
34521112
|
| PMC |
PMC8905705
|
| MeSH |
Animals
Bone Marrow Cells / metabolism
Calcium-Calmodulin-Dependent Protein Kinase Type 2 / genetics
Calcium-Calmodulin-Dependent Protein Kinase Type 2 / metabolism*
Humans
Mice
Mutation
Phenotype
Primary Myelofibrosis* / drug therapy
Primary Myelofibrosis* / genetics
Receptors, Thrombopoietin
|
| IF |
4.91
|
| リソース情報 |
| ヒト・動物細胞 |
Ba/F3(RCB0805) |
